Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update

Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update PR Newswire

* Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome * Once-weekly injectable MC4R selective peptide agonist Phase 1 SAD/MAD study targeted to initiate in the first half of calendar 2027, with initial data targeted in the second half of 2027 * Oral MC4R selective agonist Phase 1 SAD/MAD study targeted to initiate in the second half of calendar 2027, with initial data targeted in the first half of 2028 * Multiple lipidated and non-lipidated peptide compounds demonstrated potent MC4R agonist activity but are not agonists at melanocortin 1 receptor (MC1R), supporting the potential to minimize or eliminate MC1R-mediated hyperpigmentation * Fiscal 2026 collaboration and license revenue totaled $13.2 million, with approximately $9.4 million related to Boehringer Ingelheim and $3.8 million of non-cash license revenue under the Altanispac Labs agreement * Cash and cash equivalents were $7.5 million as of June 30, 2026; additional funding will be required to continue advancing development programs and fund operations * Conference call and webcast scheduled for September 28, 2026, at 11:00 a.m. ET PRINCETON, N.J., Sept. 28, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor ("MCR") system, today reported financial results for the fiscal year ended June 30, 2026 and provided an update on its MC4R-focused obesity development programs and partnering activities.